For a long time, stem cell therapy has been discussed as a promising but distant possibility. Something is being tested in laboratories and clinical trials, but not yet part of everyday medical care.
That is starting to change.
In early 2026, two stem cell treatments were officially approved for clinical use in China, one for lupus, a chronic autoimmune disease, and one for type 2 diabetes. Both treatments are now being offered to real patients in a clinical setting.
What kind of stem cells are being used?
These treatments use mesenchymal stem cells (MSCs) derived from umbilical cord tissue. MSCs are a type of cell known for their ability to reduce inflammation and support the body’s own repair processes. They are not the same as embryonic stem cells, and their use does not involve embryos.
Where and how are these treatments being delivered?
The treatments are being carried out at a hospital operating within the Beidaihe Life and Health Innovation Demonstration Zone in China, a government-supported area specifically designed to bring advanced medical technologies into structured, regulated clinical use. The collaboration involves a clinical hospital, a research center, and Beike Biotechnology, the company responsible for producing the cell therapies.
Importantly, these are not experimental procedures offered outside of oversight. The cell products are manufactured under strict quality and safety standards, with every step, from collection to transport, tracked and documented.
Why does this matter for patients with lupus or diabetes?
Lupus is a disease where the immune system mistakenly attacks healthy tissue, causing chronic inflammation and damage to joints, skin, kidneys, and other organs. Managing it can be difficult, and many patients continue to experience symptoms despite treatment.
Type 2 diabetes affects the body’s ability to regulate blood sugar, and while it can be managed with medication and lifestyle changes, it remains a significant burden for millions of people worldwide.
For patients where standard treatments have not provided sufficient relief, having a regulated, clinically supervised stem cell option represents a real expansion of what is available to them.
Is this proven to work?
Stem cell therapy is still a developing field. These approvals mark an important step, but they are not the end of the story. Real-world use in clinical settings will generate the kind of long-term data needed to better understand how effective these treatments are, for which patients, and under what conditions.
What is clear is that these therapies have met the standards required for approved clinical use in China, which means they have passed a regulatory threshold, not simply been made available as an experiment.
The bigger picture
What makes this development worth paying attention to is not just the two approvals themselves — it is the model behind them. A government-supported zone, a specialized research center, and a regulated cell manufacturer working together to bring a complex therapy into practice in a structured, traceable way.
This kind of coordinated approach may offer a blueprint for how other countries and institutions begin to integrate stem cell therapies into mainstream medicine responsibly.
We are still in the early stages. But for patients living with conditions like lupus and type 2 diabetes, the distance between cutting-edge research and real treatment options just got a little shorter.